This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mount, K. L. Articles by Pickworth, K. K. Search for Related Content Social Bookmarking                         What's this?

Intravenous Amiodarone for the Treatment of Atrial Fibrillation in the Nonsurgical Patient

Department of Pharmacy, The Ohio State University Medical Center, Columbus, Ohio

Kerry K. Pickworth, PharmD

The Ohio State University Medical Center, Room 368 Doan Hall, 410 West 10th Ave, Columbus, OH 43210, pickworth-1{at}medctr.osu.edu

Purpose: To review the literature to define the efficacy of intravenous (IV) amiodarone in the treatment of atrial fibrillation in the nonsurgical patient. Method: A MEDLINE search was conducted using the key words "intravenous amiodarone" and "atrial fibrillation." All trials evaluating the use of intravenous amiodarone in the surgical setting were excluded. Results: Twenty articles were identified, which were divided into acute and chronic atrial fibrillation. Within the acute setting, IV amiodarone was used alone, compared to a placebo-control, or compared to active drug regimens. In the trials without a control group, it was difficult to determine how much of the effect was due to spontaneous conversion. When compared to placebo, IV amiodarone offered a 61% to 92% conversion at 24 hours. Compared to active drug therapy, there was a trend to increased efficacy at 24 hours. However, amiodarone was no more effective for the conversion of atrial fibrillation than alternative therapies. In the case of chronic atrial fibrillation, intravenous amiodarone had no benefit. The incidence of thrombophlebitis, bradycardia, and hypotension was quite high, reported to be around 15% to 30% in many of the trials. Conclusion: The use of intravenous amiodarone should not be recommended as the first line agent for the conversion of atrial fibrillation.

Key Words: amiodarone • atrial fibrillation • intravenous infusion

Journal of Pharmacy Practice, Vol. 15, No. 4, 356-368 (2002)
DOI: 10.1177/089719002129041340


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?